Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Irritable Bowel Syndrome, March 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 119 articles: HTML format

Single Articles

1. BEKTAS A
   Non-celiac Gluten Sensitivity: A New Clinical Entity or Growing Controversy?
   Euroasian J Hepatogastroenterol. 2025;15:170-172.
   PubMed    
   Abstract available
   
   

2. LI Q, Fan M, Gao A, Qin L, et al
   Evaluating the real-world safety of cholestyramine for the treatment of hyperlipidemia: disproportionality analysis of FAERS data.
   Front Med (Lausanne). 2026;13:1765949.
   PubMed    
   Abstract available
   
   

3. QUAN Z, Song W, Huang Q, Wang J, et al
   The effects of different exercise interventions on clinical outcomes of irritable bowel syndrome and their potential mechanisms: a systematic review and network meta-analysis.
   Front Immunol. 2026;17:1730624.
   PubMed    
   Abstract available
   
   

4. COSIMATO I, Brescia A, Franci G, Casolaro V, et al
   Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota.
   Pharmaceutics. 2026;18:197.
   PubMed    
   Abstract available
   
   

5. DE STEFANIS S, Colavita F, Maggi F, Antonioli M, et al
   SARS-CoV-2 Persistence and the Gut Microbiota: New Insights into Long COVID Pathogenesis.
   Viruses. 2026;18:247.
   PubMed    
   Abstract available
   
   

6. COLECCHIA L, Marasco G, Meacci D, Cremon C, et al
   Nutritional Management of Irritable Bowel Syndrome.
   Nutrients. 2026;18:699.
   PubMed    
   Abstract available
   
   

7. INDRIO F, Di Mauro A, Perrone G, Greco A, et al
   Long-Term Efficacy of Limosilactobacillus reuteri DSM17938 in the Prevention of Functional Abdominal Pain Disorders.
   Nutrients. 2026;18:687.
   PubMed    
   Abstract available
   
   

8. SEIDITA A, Mansueto P, Pistone M, Soresi M, et al
   Atopy and Other Sensitivities in Non-Celiac Wheat Sensitivity: Is There an Associated Hypersensitivity Background? (dagger).
   Nutrients. 2026;18:609.
   PubMed    
   Abstract available
   
   

9. PAMUEANGMUN P, Kham NNN, Kanpiengjai A, Saenjum C, et al
   Probiotic Potential of Weizmannia coagulans MA42, an Endospore-Forming Probiotic Bacterium Capable of Dietary Fiber Digestion.
   Foods. 2026;15:710.
   PubMed    
   Abstract available
   
   

10. TALASILA S, Ahmed A, Malick H, Nadir U, et al
    Modestly Increased Incidence of Irritable Bowel Syndrome in Hidradenitis Suppurativa: A Retrospective Cohort Study Using TriNetX.
    Int J Dermatol. 2026 Feb 26. doi: 10.1111/ijd.70357.
    PubMed    
    
    
    

11. XIONG N, Mi Q, Sun Q, Liu Q, et al
    Disrupted Prefrontal Regulation of Social Rejection in Irritable Bowel Syndrome.
    Psychother Psychosom. 2026 Feb 26:1-26. doi: 10.1159/000551116.
    PubMed    
    Abstract available
    
    

12. ARGYRIOU K, Manolakis A, Tsakiridou E, Christodoulou D, et al
    Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle.
    Acta Gastroenterol Belg. 2026;89:65-77.
    PubMed    
    Abstract available
    
    

13. MARASCO G, Meacci D, Sarnelli G, Tosetti C, et al
    Diarrhea management: from pathophysiology to microbiota modulation.
    Therap Adv Gastroenterol. 2026;19:17562848261424324.
    PubMed    
    Abstract available
    
    

14. STURKENBOOM R, Essers BAB, Masclee AAM, Keszthelyi D, et al
    Gender-dependent preferences of medical professionals in treatment choices for irritable bowel syndrome: results from an exploratory study.
    BMC Gastroenterol. 2026 Feb 25. doi: 10.1186/s12876-026-04660.
    PubMed    
    
    
    

15. MISHRA AS, Ghosh B, Malliappan SP, Dutta G, et al
    Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.
    RSC Adv. 2026;16:10022-10059.
    PubMed    
    Abstract available
    
    

16. MI Z, Huaien BU, Dongjun W, Naijin Z, et al
    Efficacy of Tongxie Yaofang compared with pinaverium bromide on irritable bowel syndrome with liver depression and spleen deficiency: a systematic review and Meta-analysis.
    J Tradit Chin Med. 2026;46:14-21.
    PubMed    
    Abstract available
    
    

17. TANG Y, He Z, Zhang Q, Liu Y, et al
    Hippocampal Neuronal Ferroptosis Driven by Lipocalin-2 Mediates Comorbid Visceral Pain and Anxiety in Irritable Bowel Syndrome.
    Mol Neurobiol. 2026;63:469.
    PubMed    
    Abstract available
    
    

18. ZHANG HF, Huang R, Jiang F, Li F, et al
    [Clinical study of acupuncture at force-sensitive acupoints in treatment of diarrhea-predominant irritable bowel syndrome].
    Zhen Ci Yan Jiu. 2026;51:233-239.
    PubMed    
    Abstract available
    
    

19. GHOSH D, Sharma R, Katiyar D, Mittal A, et al
    An overview of commercially available polymers for colon-targeted drug delivery systems.
    J Biomater Sci Polym Ed. 2026 Feb 23:1-39. doi: 10.1080/09205063.2026.2628305.
    PubMed    
    Abstract available
    
    

20. PALENCA I, Franzin SB, Pesce M, Sarnelli G, et al
    Rifaximin's therapeutic spectrum: approved indications and experimental insights into emerging uses.
    Pharmacol Rep. 2026 Feb 23. doi: 10.1007/s43440-026-00830.
    PubMed    
    
    
    

21. ATALAY BR, Yurtseven B, Akbaba E, Ayaz F, et al
    Immunomodulatory Effects of Hyoscine Butylbromide on Mammalian Macrophages.
    Fundam Clin Pharmacol. 2026;40:e70075.
    PubMed    
    Abstract available
    
    

22. VENTURA L, Keaser ML, Hernandez-Rojas LG, Shahed M, et al
    Sex-dependent changes in insular cortex connectivity in a rat model of comorbid pain.
    bioRxiv [Preprint]. 2026 Feb 10:2026.02.07.704080.
    PubMed    
    Abstract available
    
    

23. ASHAOLU TJ, Suttikhana I
    Probiotic therapeutics: A critical review of mechanisms, clinical efficacy, and the frontier of precision microbiome modulation.
    Int Immunopharmacol. 2026;175:116412.
    PubMed    
    Abstract available
    
    

24. GROS M, Gros-Baneres B, Mesonero JE, Latorre E, et al
    Dietary intake as a tool to support diagnosis of irritable bowel syndrome.
    Med Clin (Barc). 2026;166:107388.
    PubMed    
    Abstract available
    
    

25. LI Z, Morgan L, Gong TM, Mula M, et al
    Bidirectional Associations Between Anxiety and Gastrointestinal Disorders: A Retrospective Cohort Study Using the TriNetX Database.
    Cureus. 2026;18:e102747.
    PubMed    
    Abstract available
    
    

26. COTTON CEM, Hopper AD, Sanders DS
    Are we missing early pancreatic dysfunction? Expanding faecal elastase testing beyond pancreatic disease.
    Curr Opin Gastroenterol. 2026 Mar 4. doi: 10.1097/MOG.0000000000001163.
    PubMed    
    Abstract available
    
    

27. WU X, Tang Y, He Z, Yang F, et al
    EXPRESS: miRNA-let7b5p Alleviates Visceral Hypersensitivity by Inhibiting the Activation of Spinal Microglial in Male IBS-like Rats.
    Mol Pain. 2026 Mar 4:17448069261430202. doi: 10.1177/17448069261430202.
    PubMed    
    Abstract available
    
    

28. LIU ZH, Liu YQ, Zhang QL, Lin C, et al
    [Spinal lncRNA_RT1-CE10 attenuates chronic visceral hypersensitivity in rats with irritable bowel syndrome via inhibiting microglial activation].
    Sheng Li Xue Bao. 2026;78:246-252.
    PubMed    
    Abstract available
    
    

29. FAN F, Cao Y, He ZQ, Yang F, et al
    Oxytocin relieves visceral hypersensitivity through GABAB1-TRPV1 in rats with irritable bowel syndrome.
    Sheng Li Xue Bao. 2026;78:173-181.
    PubMed    
    Abstract available
    
    

30. ZENG L, Zhou W
    Deciphering the mitochondria-gut microbiota axis in irritable bowel syndrome: pathogenic insights and therapeutic frontiers.
    J Transl Med. 2026 Mar 2. doi: 10.1186/s12967-026-07894.
    PubMed    
    
    
    

31. LIU S, Domingo-Vidal M, Madhu B, Binyamin D, et al
    Metabotherapy for intestinal disease: using metabolites to prevent and treat disorders of the gut.
    Nat Rev Gastroenterol Hepatol. 2026 Mar 2. doi: 10.1038/s41575-026-01178.
    PubMed    
    Abstract available
    
    

32. WANG S, Zhou T, Wang X, Zhao J, et al
    Bridging the gap: Prevotella/Segatella's impact on gut barrier function and advanced cultivation strategies to realize the uses in gut health.
    Gut Microbes. 2026;18:2638001.
    PubMed    
    Abstract available
    
    

33. ALHARAZI RM, Sultan I, Alahmadi GA, Ghandour R, et al
    Association Between Stress Management Interventions and Symptom Severity in Adults With Irritable Bowel Syndrome (IBS) in Saudi Arabia.
    Cureus. 2026;18:e102466.
    PubMed    
    Abstract available
    
    

34. VIGNAL L, de Lahondes R, Gillibert A, Tavolacci MP, et al
    Metagenomic analysis of salivary microbiota in patients with anorexia nervosa and association with functional digestive disorders (ORMICAN pilot study).
    BMJ Nutr Prev Health. 2025;8:e001112.
    PubMed    
    Abstract available
    
    

35. NETO JN, Veigas KIS, Gomes LMRS, Silva LC, et al
    Prevalence and related factors of irritable bowel syndrome in women with chronic pelvic pain.
    Clinics (Sao Paulo). 2026;81:100884.
    PubMed    
    Abstract available
    
    

36. SALEH AO, Awashra A, Abouelmagd AA, Elkholy M, et al
    Vagal Nerve Stimulation for Chronic Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Neuromodulation. 2026 Feb 27:S1094-7159(26)00010.
    PubMed    
    Abstract available
    
    

37. STENMAN E, Bolmsjo BB, Nilholm C, Grundberg A, et al
    Poor self-rated health in individuals with irritable bowel syndrome but no increased 10-year cardiovascular risk: results from a Swedish population-based screening program.
    Front Cardiovasc Med. 2026;13:1702012.
    PubMed    
    Abstract available
    
    

38. KHOLWADWALA AS, Quigley EMM
    Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth: Are They Overdiagnosed?
    Acta Gastroenterol Latinoam. 2025;55:276-291.
    PubMed    
    Abstract available
    
    

39. ALSMADI MM
    P-glycoprotein-mediated impairment of doxorubicin clearance in inflammatory bowel disorders: Mechanistic insights from rat studies and whole-body physiologically based pharmacokinetic modeling.
    Drug Metab Dispos. 2026;54:100254.
    PubMed    
    Abstract available
    
    

40. VAIDYULA VR, Kundu RV
    Vitiligo and Risk of Gastrointestinal Disorders in the United States: A Case-Control Study.
    Arch Dermatol Res. 2026;318:119.
    PubMed    
    
    
    

41. SHAH Q, Soldera J
    Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review.
    World J Methodol. 2026;16:107169.
    PubMed    
    Abstract available
    
    

42. PRODAN R, Soldera J
    Mirtazapine for the treatment of irritable bowel syndrome: A systematic review.
    World J Methodol. 2026;16:107908.
    PubMed    
    Abstract available
    
    

43. HUO T, Huang X, Liao J, Zhang H, et al
    The bidirectional effects and mechanisms of the oral and gut microbiomes: a narrative review.
    Front Immunol. 2026;17:1697413.
    PubMed    
    Abstract available
    
    

44. NEWMAN-BOOTH A, Fairhurst E, Vasant DH
    Racial Disparities in the Diagnosis and Management Between Secondary Care Ethnic Minority and White British Patients With Irritable Bowel Syndrome.
    Neurogastroenterol Motil. 2026;38:e70272.
    PubMed    
    Abstract available
    
    

45. KIM YS, Park SY, Kang SJ, Lee MW, et al
    Clinical Guidance and Practical Recommendations for Probiotic Use in Patients With Irritable Bowel Syndrome, Functional Constipation, and Clostridium difficile Infection Considering Sex-based Differences.
    J Neurogastroenterol Motil. 2026 Mar 10. doi: 10.5056/jnm25221.
    PubMed    
    Abstract available
    
    

46. ARCHANA B, Priyathersini N, Mathangi DC
    Improvement from Irritable Bowel Syndrome and Anxiety Through Integrative Yoga, Meditation and Naturopathy: A Case Report.
    Adv Mind Body Med. 2026 Mar 11:ADV1463.
    PubMed    
    Abstract available
    
    

47. FALL AAA, Gueye MN, Diouf MN, Toure B, et al
    Functional Bowel Disorders: A Retrospective Descriptive Study in Dakar, Senegal.
    Cureus. 2026;18:e103082.
    PubMed    
    Abstract available
    
    

48. BYKOVA SV, Dbar SR, Sabelnikova EA, Belostotsky NI, et al
    [Justification for the use of a FODMAP diet in patients with irritable bowel syndrome: focus on small intestinal disaccharidase activity].
    Ter Arkh. 2026;98:99-104.
    PubMed    
    Abstract available
    
    

49. TANG W, Wang J, Wang W, Xue J, et al
    Reviewing the Peripheral and Central Mechanisms of Visceral Hypersensitivity in Intestinal Disorders.
    Int J Med Sci. 2026;23:1121-1143.
    PubMed    
    Abstract available
    
    

50. CHEN L, Yan Y, Shi X, Chen R, et al
    Central amygdala HDAC6 contributes to visceral hypersensitivity and affective comorbidities in IBS-like rats.
    Int Immunopharmacol. 2026;176:116466.
    PubMed    
    Abstract available
    
    

51. HUANG LH, Wang YH, Wu TJ, Lin FY, et al
    Association Between Rheumatoid Arthritis and Gastrointestinal Comorbidities: Evidence From Taiwan's National Health Insurance Database.
    Int J Rheum Dis. 2026;29:e70588.
    PubMed    
    Abstract available
    
    

52. VERAZA DI, Waseem MR, Venezia J, Montero AM, et al
    Perceived Utility of Cognitive Behavioral Therapy in People With Bowel Disorders of Gut-Brain Interaction.
    Neurogastroenterol Motil. 2026;38:e70283.
    PubMed    
    Abstract available
    
    

53. SUJAN AC, Major J, Groenewald CB, Rabbitts JA, et al
    National Medical Expenditures Associated With Pediatric Disorders of Gut-Brain Interaction in the United States.
    Neurogastroenterol Motil. 2026;38:e70279.
    PubMed    
    Abstract available
    
    

54. BAHETI R, Deshkar S, Jadhav S, Mule K, et al
    Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal inflammation.
    Food Res Int. 2026;230:118598.
    PubMed    
    Abstract available
    
    

55. BURNS GL, Roberts F, Wark JA, Fowler S, et al
    Serological and faecal markers of irritable bowel syndrome: a systematic review and meta-analysis.
    EBioMedicine. 2026;126:106198.
    PubMed    
    Abstract available
    
    

56. GREEN KM, Shin SM, Jha RK, Kumar A, et al
    Current and emerging approaches to manage chronic inflammatory gut disorders.
    Front Cell Infect Microbiol. 2026;16:1762119.
    PubMed    
    Abstract available
    
    

57. HUANG R, Yu S, Xu W, Tao W, et al
    Combining network Pharmacology, molecular Simulation, and animal experiments to explore the molecular mechanisms of Tongxie Yaofang in the treatment of Diarrhea-Characterized irritable bowel syndrome comorbid with type 2 diabetes mellitus.
    In Silico Pharmacol. 2026;14:88.
    PubMed    
    Abstract available
    
    

58. SUGAYA N, Izawa S, Sasaki T
    Correction: Effects of irritable bowel syndrome and related cognitive-behavioral and occupational stress factors on the productivity and abdominal symptoms of Japanese workers: a longitudinal study.
    Biopsychosoc Med. 2026;20:5.
    PubMed    
    
    
    

59. LUO Y, Cao J, Li B, Wang J, et al
    Global landscape analysis of clinical trials on gut microbiota modulation therapies for irritable bowel syndrome.
    Front Med (Lausanne). 2026;13:1737537.
    PubMed    
    Abstract available
    
    

60. JEONG CK, Kim DJ, Yoon SH, Lee SW, et al
    Investigating the Gut-Brain Axis in Adolescents With Mood Disorders and Functional Gastrointestinal Symptoms.
    Psychiatry Investig. 2026;23:345-352.
    PubMed    
    Abstract available
    
    

61. MAZZAWI T, Haj Ali S, Nylund K, Gilja OH, et al
    Sigmoid wall thickness correlates with fecal calprotectin during irritable bowel syndrome exacerbation.
    Med Ultrason. 2026 Mar 2. doi: 10.11152/mu-4592.
    PubMed    
    Abstract available
    
    

62. CANKURTARAN RE, Karpuzcu HC, Ataman E, Aydin G, et al
    Effects of Earthquake Fear and Post-Traumatic Stress Disorder on Patients with Irritable Bowel Syndrome after a Major Earthquake in Turkiye: A Multicenter Study.
    Turk J Gastroenterol. 2026;37:387-396.
    PubMed    
    Abstract available
    
    

63. HONG L, Ma L, Dong J, Li X, et al
    Metabolic disparities of potentially toxic components derived from Psoraleae Fructus and Euodiae Fructus within the Sishen wan influenced by varying compatibilities and physiological conditions in an in vitro gut microbiota model.
    J Pharm Biomed Anal. 2026;275:117460.
    PubMed    
    Abstract available
    
    

64. HADLANDSMYTH K, Driscoll MA, Adamowicz JL, Garvin L, et al
    Rural specialty care for Veterans with the chronic overlapping pain conditions: Fibromyalgia, migraine, or irritable bowel syndrome.
    J Rural Health. 2026;42:e70132.
    PubMed    
    Abstract available
    
    

65. XIANG RL, Liang FY, Liu SZ, Xie MT, et al
    [Effect of different frequencies electroacupuncture at "Zusanli"(ST36) on visceral sensitivity and adrenocorticotropin releasing factor expression in IBS mice].
    Zhen Ci Yan Jiu. 2025;51:323-331.
    PubMed    
    Abstract available
    
    

66. ZHANG R, Ge M, Hu M, Zhao Y, et al
    Magnesium Deficiency Accelerates Gut Aging and Increases Susceptibility to Colitis.
    Aging Cell. 2026;25:e70446.
    PubMed    
    Abstract available
    
    

67. WU J, Zhuang S, Zhuang Z, Qu L, et al
    Classifying irritable bowel syndrome using spatio-temporal graph convolution networks on brain functional MRI data.
    Brain Commun. 2026;8:fcag062.
    PubMed    
    Abstract available
    
    

68. PENG SH, Yao Y, Zhang GK, Luan Z, et al
    [The association between adverse childhood experiences and comorbid anxiety/depression in irritable bowel syndrome: A UK Biobank Study].
    Zhonghua Nei Ke Za Zhi. 2026;65:279-288.
    PubMed    
    Abstract available
    
    

69. PETERS L, Matysiak A, Hubener S, Lohse AW, et al
    Course and predictors of somatic symptom disorder in irritable bowel syndrome and ulcerative colitis: A longitudinal analysis from the SOMA.GUT-RCT.
    Gen Hosp Psychiatry. 2026;100:72-82.
    PubMed    
    Abstract available
    
    

70. CLAUSEN MT, Sverdrup H, Brevik A, Molin M, et al
    Time-Restricted Eating and Symptom Severity in Irritable Bowel Syndrome: Results from a Pilot Study.
    Nutrients. 2026;18:765.
    PubMed    
    Abstract available
    
    

71. MERLO EM, Myles LAM, Alibrandi A
    Psychosomatic Features of Irritable Bowel Syndrome: The Role of Alexithymia in Patient Health-Related Quality of Life-A Cross-Sectional Study.
    Healthcare (Basel). 2026;14:562.
    PubMed    
    Abstract available
    
    

72. BALLENA-CAICEDO J, Zuzunaga-Montoya FE, Acosta-Porzoliz R, Garcia-Ahumada F, et al
    Probiotics in Irritable Bowel Syndrome: An Umbrella Review of 27 Systematic Reviews on Methodological Quality and Certainty of Evidence.
    J Clin Med. 2026;15:1727.
    PubMed    
    Abstract available
    
    

73. QUAN Y, Zhou T
    Efficacy and mechanisms of vagus nerve stimulation in irritable bowel syndrome: a comprehensive literature review.
    Front Immunol. 2026;17:1769070.
    PubMed    
    Abstract available
    
    

74. ACHEAMPONG S, Udoyeh C, Darko P, Omeludike EK, et al
    Rifaximin-Induced Rhabdomyolysis.
    Cureus. 2026;18:e104091.
    PubMed    
    Abstract available
    
    

75. ZHU M, Li L, Zhang D, Fang Y, et al
    Comparative effectiveness and underlying mechanisms of acupuncture approaches in IBS-D animal models: a protocol for systematic review and network meta-analysis.
    Syst Rev. 2026 Mar 26. doi: 10.1186/s13643-026-03162.
    PubMed    
    Abstract available
    
    

76. VAN ROOYEN DM, Cai M, Nair BR, Talley NJ, et al
    Irritable bowel syndrome in the elderly: epidemiology, diagnosis, treatment, and relationship with frailty.
    Expert Rev Gastroenterol Hepatol. 2026.
    PubMed    
    Abstract available
    
    

77. KOUSAR S, Manzoor I, Muhammad S, Almohaimeed HM, et al
    Immunoinformatic-based design of a multi-epitope subunit vaccine against Ruminococcus torques using subtractive proteomics and molecular dynamics simulations.
    Sci Rep. 2026 Mar 26. doi: 10.1038/s41598-026-45572.
    PubMed    
    Abstract available
    
    

78. SINGH P, Nee JW, Ballou S, Lee A, et al
    ORP-101 in Irritable Bowel Syndrome with Diarrhea: A Phase II Randomized, Controlled Trial.
    Clin Gastroenterol Hepatol. 2026 Mar 24:S1542-3565(26)00216.
    PubMed    
    Abstract available
    
    

79. CHEN W, Li T, Chen S, Bai L, et al
    PM(2.5) exacerbates brain injury in diarrhea-predominant irritable bowel syndrome mice via the disruption of the microbiota-gut-brain axis and the restoring effect of resveratrol.
    Environ Pollut. 2026 Mar 24:128011. doi: 10.1016/j.envpol.2026.128011.
    PubMed    
    Abstract available
    
    

80. THAKUR ER
    Meditative Movement Approaches for Irritable Bowel Syndrome.
    Gastroenterol Hepatol (N Y). 2026;22:129-131.
    PubMed    
    
    
    

81. YE B, Fu Z, Zhou X, Wang S, et al
    Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.
    J Inflamm Res. 2026;19:578822.
    PubMed    
    Abstract available
    
    

82. WU J, Du S, Sun Y, Ye J, et al
    Evaluation of the effectiveness of exercise therapy for irritable bowel syndrome: a systematic review and meta-analysis.
    Front Med (Lausanne). 2026;13:1771521.
    PubMed    
    Abstract available
    
    

83. DWAIRI R, Al-Refu K, Al Tah B, Al Saraireh T, et al
    Female Sexual Dysfunction and Irritable Bowel Syndrome: A Cross-Sectional Study in Jordanian Women.
    Int J Womens Health. 2026;18:563741.
    PubMed    
    Abstract available
    
    

84. LU H
    Relationship between small intestinal bacterial overgrowth and irritable bowel syndrome and the efficacy of rifaximin intervention: a systematic review and meta-analysis.
    Front Microbiol. 2026;17:1780567.
    PubMed    
    Abstract available
    
    

85. SUWANNAHITATORN P
    Genetic diversity and zoonotic transmission potential of Blastocystis sp. in Southeast Asia: A scoping review of molecular evidence.
    Parasite Epidemiol Control. 2026;33:e00492.
    PubMed    
    Abstract available
    
    

86. KORETZ RL
    JPEN Journal Club 100. It depends on the control.
    JPEN J Parenter Enteral Nutr. 2026 Mar 25. doi: 10.1002/jpen.70086.
    PubMed    
    
    
    

87. SANTUCCI NR, Fessler B, Shah P, Sahay R, et al
    Polysomnography demonstrates worse sleep in children and adolescents with disorders of gut-brain interaction (DGBI) compared to healthy children: A case-control study.
    Sleep Med. 2026;143:108907.
    PubMed    
    Abstract available
    
    

88. JOHNSSON A, Ljotsson B, Liliequist BE, Lidin M, et al
    Digital Cognitive Behavioral Therapy for Cardiac Anxiety After Myocardial Infarction: Effects on Disease-Specific Health Status-Randomized Trial Results.
    J Am Coll Cardiol. 2026 Mar 25:S0735-1097(26)05438.
    PubMed    
    
    
    

89. JOHNSSON A, Ljotsson B, Liliequist BE, Lidin M, et al
    Digital Cognitive Behavioral Therapy for Cardiac Anxiety After Myocardial Infarction: Effects on Disease-Specific Health Status-Detailed Methods and Protocol.
    JACC Adv. 2026 Mar 25:102669. doi: 10.1016/j.jacadv.2026.102669.
    PubMed    
    Abstract available
    
    

90. GUO Y, Wang D, Chen M, Wei X, et al
    Impact of Electroacupuncture on the Expression Profile of the Anterior Cingulate Cortex in a Rat Model of Irritable Bowel Syndrome Based on Transcriptome Sequencing and Bioinformatics Analysis.
    J Pain Res. 2026;19:574208.
    PubMed    
    Abstract available
    
    

91. WENG RX, Gao Y, Zhang CH, Yan RY, et al
    EXPRESS: The enhanced analgesic effects of electroacupuncture and repetitive transcranial magnetic stimulation on visceral pain via ventral lateral septal nucleus.
    Mol Pain. 2026 Mar 24:17448069261428970. doi: 10.1177/17448069261428970.
    PubMed    
    Abstract available
    
    

92. YAMAZAKI T, Kurisu K, Machida T, Kunio M, et al
    Usability study to guide the development of a cognitive behavioral therapy mobile application for reducing irritable bowel syndrome symptoms.
    Biopsychosoc Med. 2026 Mar 24. doi: 10.1186/s13030-026-00354.
    PubMed    
    
    
    

93. MANNING LP, Van Den Houte M, Tuck CJ, Van Oudenhove L, et al
    Psychological Factors Predict Response to a Low Fermentable Oligo-, di-, Monosaccharide and Polyol Dietary Intervention in Irritable Bowel Syndrome: A Prospective Cohort Study.
    United European Gastroenterol J. 2026;14:e70204.
    PubMed    
    Abstract available
    
    

94. GARDELLA B, Spinillo A, Dominoni M, Tiranini L, et al
    A meta-umbrella review of risk factors for vulvodynia: evidence from demographic, psychosocial, and biomedical domains.
    J Sex Med. 2026;23:qdag072.
    PubMed    
    Abstract available
    
    

95. PULASKI M, Weber HC
    Microbiome-derived signaling molecules and the brain-gut axis: emerging mechanisms and clinical implications.
    Curr Opin Endocrinol Diabetes Obes. 2026.
    PubMed    
    Abstract available
    
    

96. SCHNEDL WJ, Michaelis S, Schrittwieser R, Enko D, et al
    Elevated fecal calprotectin values appear more common following esophagogastric than colon surgery.
    J Surg Case Rep. 2026;2026:rjag188.
    PubMed    
    Abstract available
    
    

97. KATSIAFLAKA A, Doulberis M, Podaropoulou M, Katsiaflaka G, et al
    Impact of pediatric gastrointestinal disorders on learning and cognitive development in schoolchildren.
    Ann Gastroenterol. 2026;39:174-183.
    PubMed    
    Abstract available
    
    

98. BOR S, Ozen H, Kalkan IH, Akyuz F, et al
    Expert Opinion on the Efficacy and Safety of Antispasmodics with a Focus on Irritable Bowel Syndrome.
    Turk J Gastroenterol. 2025;36.
    PubMed    
    Abstract available
    
    

99. KUO HY, Hsu TW, Chu CS, Tsai SJ, et al
    Bidirectional association between irritable bowel syndrome and depression among probands and unaffected siblings: A nationwide population-based study.
    Gen Hosp Psychiatry. 2026;100:87-92.
    PubMed    
    Abstract available
    
    

100. GARCIA-CEDILLO MF, Huerta-de la Torre MF, Arenas-Martinez JS, Coss-Adame E, et al
     Effects of a Personalised FODMAP Diet Versus the National Institute for Health and Care Excellence (NICE) Dietary Advice on Symptom Control in Patients With Irritable Bowel Syndrome: Randomised Clinical Trial.
     Aliment Pharmacol Ther. 2026 Mar 5. doi: 10.1111/apt.70601.
     PubMed    
     Abstract available
     
     

101. SASEGBON A, Vasant DH
     Editorial: New Insights Into the Aetiopathogenesis of Post-Infective Irritable Bowel Syndrome and Functional Dyspepsia: A Significant Step Forward but What Next?
     Aliment Pharmacol Ther. 2026 Mar 17. doi: 10.1111/apt.70627.
     PubMed    
     
     
     

102. ELDESOUKI MH, Kloub M, Elfert K, Ibrahim A, et al
     Cohort Study: Long-Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients.
     Aliment Pharmacol Ther. 2026 Mar 13. doi: 10.1111/apt.70602.
     PubMed    
     Abstract available
     
     

103. WHELAN K
     Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome.
     Aliment Pharmacol Ther. 2026 Mar 25. doi: 10.1111/apt.70626.
     PubMed    
     
     
     

104. COSS-ADAME E, Garcia-Cedillo MF, Huerta-de la Torre MF, Arenas-Martinez JS, et al
     Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply.
     Aliment Pharmacol Ther. 2026 Mar 25. doi: 10.1111/apt.70631.
     PubMed    
     
     
     

105. BYALE A, Palsson OS, Simren M, Tack J, et al
     Bloating and Distention Patients Form 6 Distinct Latent Clusters Based on Symptoms, Diet, Psychosocial, and Quality-of-Life Parameters.
     Am J Gastroenterol. 2026;121:754-766.
     PubMed    
     Abstract available
     
     

106. BERRY SK, Varma S, Basnayake C, Ahn JC, et al
     Virtual Multidisciplinary GI Care Clinic Improves Patient Engagement, Satisfaction, and Outcomes at Reduced Costs and Healthcare Utilization: A Prospective Cohort Study.
     Am J Gastroenterol. 2026 Mar 20. doi: 10.14309/ajg.0000000000004002.
     PubMed    
     Abstract available
     
     

107. COLECCHIA L, Marasco G, Capelli C, Facciorusso A, et al
     Antibiotic use during gastrointestinal infections increases the risk of developing irritable bowel syndrome: a Systematic Review and Meta-Analysis.
     Am J Gastroenterol. 2026 Mar 20. doi: 10.14309/ajg.0000000000004001.
     PubMed    
     Abstract available
     
     

108. COLOMIER E, Jones MP, Holvoet L, Van den Houte K, et al
     symptom patterns outside the rome iv consensus in eastern and western patients with a disorder of gut-brain interaction.
     Am J Gastroenterol. 2026 Mar 17. doi: 10.14309/ajg.0000000000003996.
     PubMed    
     Abstract available
     
     

109. FERREIRA AI, Arieira C, Campelo P, Xavier S, et al
     Three is not a crowd: improving the study of chronic constipation.
     Eur J Gastroenterol Hepatol. 2026 Feb 23. doi: 10.1097/MEG.0000000000003164.
     PubMed    
     Abstract available
     
     

110. BARAZANJI N, Sjodahl J, Orell G, Evripidou M, et al
     From Gut Feeling to Gray Matter: Mapping Defecation Urgency in Irritable Bowel Syndrome.
     Gastroenterology. 2026 Feb 26:S0016-5085(26)00103.
     PubMed    
     Abstract available
     
     

111. CAMILLERI M
     Comments on "Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Improves Colonic Barrier Function and Mast Cell Activation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Mechanistic Trial".
     Gastroenterology. 2026 Mar 12:S0016-5085(26)00236.
     PubMed    
     
     
     

112. MEHTA S, Agarwal S, Pachisia AV, Sachdev V, et al
     A single test strategy using spot fecal bile acid test may be a feasible strategy for the diagnosis of bile acid malabsorption.
     Indian J Gastroenterol. 2026 Mar 19. doi: 10.1007/s12664-026-01972.
     PubMed    
     Abstract available
     
     

113. LI X
     Reconsidering Bloating as a Core Endpoint in IBS-C: Commentary on Brenner et al. (2025).
     J Gastroenterol Hepatol. 2026 Feb 26. doi: 10.1111/jgh.70320.
     PubMed    
     
     
     

114. TANG ASP, Quek J, Sulaimi F, Sim B, et al
     Probiotics for Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis With Trial Sequential Analysis.
     J Gastroenterol Hepatol. 2026 Mar 12. doi: 10.1111/jgh.70322.
     PubMed    
     Abstract available
     
     

115. TAO X
     Comment on "Associations of Long-Term Night Shift Work With Incident Irritable Bowel Syndrome: A Population-Based Cohort Study".
     J Gastroenterol Hepatol. 2026 Mar 21. doi: 10.1111/jgh.70363.
     PubMed    
     
     
     

116. QUATRALE G, Chirico N, Colecchia L, Stella G, et al
     Prevalence of disorders of gut-brain-interaction in pediatric patients with in-remission inflammatory bowel disease: An Italian multicenter study.
     J Pediatr Gastroenterol Nutr. 2026 Feb 23. doi: 10.1002/jpn3.70386.
     PubMed    
     Abstract available
     
     

117. CARPAY NC, Kamphorst K, van Elburg RM, Vlieger AM, et al
     Antibiotics in the first week of life are not associated with functional gastrointestinal disorders at 9-12 years of age.
     J Pediatr Gastroenterol Nutr. 2026 Mar 23. doi: 10.1002/jpn3.70402.
     PubMed    
     Abstract available
     
     

118. TATTAN M, Hanssen DJC, Rosmalen JGM
     Who receives a diagnostic label for fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome? A study in the lifelines cohort.
     J Psychosom Res. 2026;205:112609.
     PubMed    
     Abstract available
     
     

119. SINGH P, Lee A, Sheth NM, Chey WD, et al
     Chronic, Noninfectious Diarrhea: A Review.
     JAMA. 2026 Mar 2. doi: 10.1001/jama.2026.0872.
     PubMed    
     Abstract available